JPRN-UMIN000011361已完成2 期
Phase II study of biweekly cetuximab therapy for unresectable colorectal cancer - Phase II study of biweekly cetuximab therapy
Department of Surgical Oncology Osaka City University0 个研究点目标入组 10 人开始时间: 2013年8月3日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)other co-existing malignancy 2)severe concurrent medical orpsychiatric illness 3)patients were pregnant or lactating.
研究者
相似试验
已完成
2 期
Randomized phase II study of biweekly cetuximab versus panitumumab in patients not combination of irinotecan wild-type KRAS metastatic colorectal cancer following treatment with fluoropyrimidine and oxaliplatin chemotherapyadvanced colorectal cancerJPRN-UMIN000006899Tsukuba Center Clinical Trial Group(TCTG)90
已完成
2 期
Phase II trial of bi-weekly cetuximab for recurrent or metastatic colorectal cancerrecurrent or metastatic colorectal cancerJPRN-UMIN000006452Kobe University Hospital20
进行中（未招募）
不适用
Phase II study of cetuximab in combination with cisplatin-docetaxel in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC): a biomarker-based assessment of activity. - NDon small cell lung cancerMedDRA version: 9.1Level: LLTClassification code 10001183MedDRA version: 9.1Level: LLTClassification code 10025038EUCTR2008-008387-27-ITGRUPPO ONCOLOGICO ITALIANO DI RICERCA
进行中（未招募）
不适用
Ensayo clínico fase II con cetuximab bisemanal en combinación con oxaliplatino, 5-fluorouracilo y ácido folínico (folfox-4) en el tratamiento de primera linea del cáncer colorectal metastásico kras tipo natural.EUCTR2008-006909-16-ESACROSS:Associació Catalana per a la Recerca Oncològica i les seves implicacions sanitàries i Socials
已完成
不适用
Phase II sudy of cetuximab for the treatment of refractory or relapsed multiple myeloma Erbitux for Multiple MyelomACancerISRCTN81968533niversity of Cologne (Germany)33